Interestingly, CIS administration resulted in a significant upregulation of antioxidant enzymes activity, with an increase in GPx and GR activities around 90 and 60%, respectively, compared to control group (Figure 3b,c). The gene discussed is GSR; the disease is in situ carcinoma.